Genocury has built the echnology platforms of cutting-edge iPSC reprogramming, cell directed differentiation, and in vivo targeted delivery. We aim to produce affordable cell and gene therapy products that are available to patients and affordable by medical insurance by in vivo CAR-T and iPS-derived CAR-iNK as the featured pipeline.
Our company's team members are highly skilled, have spent years honing their skills in the GCT sector and are dedicated to the research and development of CGT, including process development, quality control, registration and application to promote pipeline research and development to reach clinical utilization.
Universal cell therapy based on autologous cells A platform with manufactures CAR-T cells In Vivo via our In Vivo Vector.
Innovated process , excellent program
High efficiency, low cost
Genetically engineered NK cells expressing CAR molecules Enhanced killing effect of CAR-NK cells targeting at tumor cells.
High safety, low cost
Efficient iNK differentiation and enhanced iNK technology platform
Customized iNK cells differentiated from iPSC to satisfy different and diverse needs of our customers
Cell-specific lentiviral vector packaging： target-oriented delivery to T/B/NK cells
iPS Cell line establishment
Cell line customization